News and Announcements
Analytica Receive R&D Tax Incentive Receipt
- Published January 18, 2016 3:14PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th January 2016, ASX Announcement
Analytica Ltd (ASX: ALT) is pleased to announce the receipt of $1,901k from the Australian Taxation Office under the Research and Development Incentive related to the financial year to 30th June 2015.
The research and development tax incentive is an initiative of the federal government to assist small companies to invest in essential research and development to be internationally competitive with new innovative products. This incentive is a welcome boost to our research funding and Analytica is grateful for the support.
The continuing investment in the research and development of the PeriCoach® has led to a best in class, non-pharmaceutical, non-surgical treatment for pelvic floor muscle disorders, particularly stress urinary incontinence and sexual function. Pelvic floor muscles exercises are recommended by the American College of Physicians as a first line treatment for urinary incontinence.
To view the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
